Market News & Trends
Alvotech & Teva Announce Filing Acceptance of US Biologics License Applications for a Proposed Biosimilar to Simponi & Simponi Aria
Alvotech and Teva Pharmaceuticals recently announced the US FDA has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech’s proposed biosimilar to Simponi and…
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of Second-Generation TriKE for the Treatment of Hematologic Malignancies
GT Biopharma, Inc. recently announced the first patient was dosed in a Phase 1 trial evaluating GTB-3650, its second-generation TriKE, for the treatment of relapsed…
US Patent Office Granted Can-Fite Namodenoson Patent for Use as Anti-Obesity Drug
Can-Fite BioPharma Ltd. recently announced its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US patent…
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced it has received written agreement from the US FDA under the Special Protocol Assessment (SPA) process on the overall design…
Fortress Biotech Announces First Patient Dosed in Phase 2 Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
Fortress Biotech, Inc. and its majority-owned subsidiary, Helocyte, Inc. recently announced the first patient was dosed in a multicenter, placebo-controlled and randomized Phase 2 clinical…
Aliri Launches qPCR to Complement Existing Lineup of Multi-Omics Platforms
Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial biology solutions for drug developers, is pleased to announce the addition of quantitative polymerase chain…
Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus
Attovia Therapeutics recently announced the first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE)…
Incannex Healthcare Announces Positive Topline Results From Pharmacokinetics Study of an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announced positive topline results from a completed pharmacokinetics (PK) and safety study of IHL-42X, a novel, oral fixed-dose combination of acetazolamide…
Lisata Therapeutics & WARPNINE Announce Encouraging Preliminary Results From Phase 1b/2a iLSTA Trial
Lisata Therapeutics, Inc. and WARPNINE Incorporated recently announced encouraging preliminary results from the Phase 1b/2a iLSTA trial (ACTRN12623000223639) evaluating certepetide (formerly LSTA1), Lisata's proprietary investigational…
Sanara MedTech Inc. Announces Exclusive License & Distribution Agreement With & Minority Investment in Biomimetic Innovations Ltd
Sanara MedTech Inc. recently announced the execution of an exclusive license and distribution agreement with Biomimetic Innovations Ltd. In tandem, Sanara agreed to contribute up…
ArriVent BioPharma Enters Exclusive License With Lepu Biopharma for an Antibody Drug Conjugate for the Treatment of Gastrointestinal Cancers
ArriVent BioPharma, Inc. recently announced it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug…
IMMvention Therapeutix Enters Strategic Collaboration With Novo Nordisk to Develop Oral Therapies
IMMvention Therapeutix, Inc. recently announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and…
Silo Pharma Advances Intellectual Property Portfolio With Provisional Patent Filing for PTSD Treatment
Silo Pharma, Inc. recently announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This application, focused on its…
Artax Biopharma Achieves Clinical Validation of First-in-Class Oral Nck Modulator for Autoimmune Disease in Phase 2a Study
Artax Biopharma, Inc. recently announced achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary oral agent AX-158. These results…
Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
Altamira Therapeutics Ltd. recently announced it has entered into a collaboration agreement with a company in the radiopharmaceutical sector to evaluate the use of the…
Bluejay Therapeutics Receives FDA Breakthrough Therapy Designation for Brelovitug for the Treatment of Chronic Hepatitis Delta
Bluejay Therapeutics recently announced its lead product candidate brelovitug (also known as BJT-778) has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for…
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination With GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
Coya Therapeutics, Inc. recently announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases. Sustained inflammatory responses…
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. recently announced it has achieved 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial of Ropidoxuridine for…
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 With Trabectedin in Certain Sarcomas
Sonnet BioTherapeutics Holdings, Inc. recently announced an expansion of its Phase 1 SB101 clinical study of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors…
Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics & Vaccines
Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, today announced it…
